In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals.

Antimicrobial agents and chemotherapy 2024 Mar 06

filter terms:

The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC50/MIC90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.

Citation

Alina Iovleva, Christi L McElheny, Erin L Fowler, Eric Cober, Erica S Herc, Cesar A Arias, Carol Hill, Keri Baum, Vance G Fowler, Henry F Chambers, Kerryl E Greenwood-Quaintance, Robin Patel, David van Duin, Robert A Bonomo, Yohei Doi. In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. Antimicrobial agents and chemotherapy. 2024 Mar 06;68(3):e0125823